Endomural therapy

• US 20020176849A1
• Filed: 02/08/2002
• Published: 11/28/2002
• Est. Priority Date: 02/09/2001
• Status: Abandoned Application

• Current Assignee: Endoluminal Therapeutics Incorporated
• Original Assignee: Endoluminal Therapeutics Incorporated
• Inventors: Slepian, Marvin J.
• Application Number:
  US10/072,766
• Publication Number:
  US 20020176849A1
• Time in Patent Office: Days
• US Class Current: 424/93.7
• CPC Class Codes: A61B 17/00491 Surgical glue applicators surgical adhesives A61L24/00; two-component delivery syringes A61M5/19
• CPC Class Codes: A61B 17/3478 Endoscopic needles, e.g. for infusion biopsy needles A61B10/0233; catheters with injection needles A61M25/0067
• CPC Class Codes: A61B 2017/00398 using powered actuators, e.g. stepper motors, solenoids
• CPC Class Codes: A61B 2017/00871 polymeric
• CPC Class Codes: A61K 9/0024 Solid, semi-solid or solidifying implants, which are implanted or injected in body tissue compositions for intravenous administration, normal injectable solutions or dispersions for, e.g. subcutaneous administration A61K9/0019; brain implants A61K9/0085; (coated) prostheses, catheters or stents A61L
• CPC Class Codes: A61M 2025/0057 Catheters delivering medicament other than through a conventional lumen, e.g. porous walls or hydrogel coatings
• CPC Class Codes: A61M 2025/0058 having an electroactive polymer material, e.g. for steering purposes, for control of flexibility, for locking, for opening or closing
• CPC Class Codes: A61M 25/00 Catheters; Hollow probes dilators A61M29/00; peritoneal catheters A61M1/285; tracheal tubes A61M16/04; for drainage A61M27/00; for uterus, vagina or rectum A61M31/00 ; for measuring or testing A61B; materials for catheters A61L29/00
• CPC Class Codes: A61P 35/00 Antineoplastic agents
• CPC Class Codes: A61P 9/10 for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Abstract

Methods, devices and materials for the treatment or repair, replacement, transplantation or augmentation of tissues in endomural zones specifically by open surgical, minimally invasive or percutaneous transmural or trans parenchymal application of polymeric material alone or in combination with bioactive agents or cells, have been developed. These methods and systems are useful to repair, alter function, replace function or augment function of the central or endomural aspects of solid organs or tubular body structures.

Claims

1. A method of treatment comprising locally penetrating and entering the body of an organ, organ component or tissue structure with minimal damage to obtain access to endomural zones of an organ.

2. The method of claim 1 further comprising depositing in the midzone therapeutic agents and systems.

3. The method of claim 2 wherein the therapeutic agents are selected from the group consisting of drugs, cells and polymers and diagnostic and/or therapeutic devices.

4. The method of claim 3 wherein the polymers may be degradable or non degradable.

5. The method of claim 3 wherein the polymers are selected from the group consisting of solid matrices, porous matrices, hydrogels, organogels, colloidal syspensions, microparticles and microcapsules, anoparticles and combinations therof.

6. The method of claim 3 wherein the drugs are selected from the group consisting of anti-infectives, antibiotics, antifungal, antihelminthic, antiparasistic agents, anticancer agents, anti-proliferative agents, anti-migratory agents, anti-inflammatory agents, metalloproteases, proteases, thromblytic agents, fibrinolytic agents, steroids, hormones, vitamins, charbohydrates, lipids proteins, peptides and enzymes.

7. The method of claim 3 wherein the drugs are proliferative growth factors selected from the group consisting of PDGF, FGF, TGF, EDGF, Epidermal GF, NGF, ILGF, Hepatocyte scatter factor, angiogenic growth factors, serum factors, collagen, laminin, tenascin, SPARC, thrombospondin, fibronectin, vimentin and other matrix factors.

8. The method of claim 3 wherein the cells are selected from the group consisting of autogenous similar cells (i.e. mesenchymal for mesenchymal) from adjacent normal zones of the same or different organs.

9. The method of claim 3 wherein the cells are selected from the group consisting of autogenous differing cells (i.e. mesenchymal for ectodermal or splenocytes for endothelial cells) from adjacent normal zones of the same or different organs.

10. The method of claim 3 wherein the cells are therapeutic factors produced by or in the form of stem cells or other progeneitor cells.

11. The method of claim 3 wherein the cells are explanted and clonally or otherwise expanded in vitro for implantation, either without genetic modification or genetically modified, before implantation.

12. The method of claim 3 wherein the therapeutic factors are selected from the group consisting of genes, plasmids, episomes, viruses, viroids, or other microorganisms for therapeutic or synthetic purpose.

13. The method of claim 3 wherein the therapeutic factors are heat shock or stress response proteins or inducers of heat shock or stress response proteins.

14. The method of claim 1 further comprising where a cavity or containment space or reservoir area does not exist in the endomural zone, creating such a space for therapeutic placement.

16. The device of claim 15 wherein the member is rigid made of metal, polymer, or composite.

17. The device of claim 15 wherein the member is flexible and comprises a catheter-like device.

18. The device of claim 15 wherein the member is attached to a single or multiple reservoirs for therapeutic agent containment and delivery.

19. The device of claim 15 wherein the member has an expansile cutter at the distal end to create a tissue space.

20. The device of claim 15 further comprising diagnostic or therapeutic sensors.

21. The device of claim 15 further comprising projectile means to ballistically transfer particles through the ectoluminal or endoluminal zone for retention in the endomural zone.

22. The device of claim 21 wherein the projectile means is selected from the group comprising mechanical acceleration, electrical transfer, spark explosion, and gas explosion.

23. The device of claim 15 further comprising means for indirect or direct guidance means.

24. The device of claim 23 wherein the means for direct guidance is selected from the group consisting of fiber optic imaging systems, endoscopes, direct tip cameras, CCD, C-MOS or other chip or electrical video systems, ultrasound or GPS positioning systems.

25. The device of claim 15 in a kit comprising a void filling material which contains electroactive agents.

26. The device of claim 15 comprising a void filling material or implant which can locally sense, store or telemeter physical, chemical or biological information.

27. The device of claim 15 comprising electoactive or electroconductive polymers which may be directly or externally activated via transcutaneous energy delivery to elicit positive or negative galvanotaxis (tissue healing or cell movement to or from based on local persistent or intermittent electrical current).

28. The device of claim 15 comprising a therapeutic for induction of angiogenesis or myogenesis.

29. The device of claim 28 comprising a therapeutic selected from the group of angiogenic growth factors, inflammatory angiogenic polymers or polymer constructs, electoactive or other microinjurious or locally stimulatory polymers.

30. The device of claim 28 comprising cells selected from the group consisting of endothelial cells, EC bone marrow precursor cells, other stems cells smooth muscle cells or precursors, combinations, neural cells or neural stem cells or combinations with above are placed.

31. The device of claim 15 for nerve regeneration.

32. The device of claim 15 comprising a bioactive polymer.

33. The device of claim 15 comprising stress response inducing agents or actual stress response proteins.

15. A device comprising a hollow tubular member with an end penetrating or cuting means causing minimal collateral damage and means for delivery of therapeutic agents into endomural tissue.